ACLX
Price
$66.00
Change
+$0.49 (+0.75%)
Updated
Dec 24 closing price
Capitalization
3.82B
63 days until earnings call
Intraday BUY SELL Signals
ACUT
Price
$0.70
Change
+$0.10 (+16.67%)
Updated
Dec 24 closing price
Capitalization
11.24M
Intraday BUY SELL Signals
Interact to see
Advertisement

ACLX vs ACUT

Header iconACLX vs ACUT Comparison
Open Charts ACLX vs ACUTBanner chart's image
Arcellx
Price$66.00
Change+$0.49 (+0.75%)
Volume$289.47K
Capitalization3.82B
Accustem Sciences
Price$0.70
Change+$0.10 (+16.67%)
Volume$772
Capitalization11.24M
ACLX vs ACUT Comparison Chart in %
ACLX
Daily Signal:
Gain/Loss:
ACUT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ACLX vs. ACUT commentary
Dec 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Hold and ACUT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 25, 2025
Stock price -- (ACLX: $66.00 vs. ACUT: $0.70)
Brand notoriety: ACLX and ACUT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 30% vs. ACUT: 98%
Market capitalization -- ACLX: $3.82B vs. ACUT: $11.24M
ACLX [@Biotechnology] is valued at $3.82B. ACUT’s [@Biotechnology] market capitalization is $11.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileACUT’s FA Score has 1 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • ACUT’s FA Score: 1 green, 4 red.
According to our system of comparison, ACUT is a better buy in the long-term than ACLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 5 TA indicator(s) are bullish while ACUT’s TA Score has 4 bullish TA indicator(s).

  • ACLX’s TA Score: 5 bullish, 5 bearish.
  • ACUT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ACLX and ACUT are a good buy in the short-term.

Price Growth

ACLX (@Biotechnology) experienced а +1.98% price change this week, while ACUT (@Biotechnology) price change was -0.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

ACLX is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACLX($3.82B) has a higher market cap than ACUT($11.2M). ACUT YTD gains are higher at: 56.083 vs. ACLX (-13.939). ACUT has higher annual earnings (EBITDA): -1.61M vs. ACLX (-209.52M). ACLX has more cash in the bank: 461M vs. ACUT (14.4K). ACUT has less debt than ACLX: ACUT (44.7K) vs ACLX (51.8M). ACLX has higher revenues than ACUT: ACLX (35.9M) vs ACUT (0).
ACLXACUTACLX / ACUT
Capitalization3.82B11.2M34,071%
EBITDA-209.52M-1.61M12,994%
Gain YTD-13.93956.083-25%
P/E RatioN/AN/A-
Revenue35.9M0-
Total Cash461M14.4K3,201,389%
Total Debt51.8M44.7K115,884%
TECHNICAL ANALYSIS
Technical Analysis
ACLXACUT
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ACLX
Daily Signal:
Gain/Loss:
ACUT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AAGPX22.840.08
+0.35%
American Beacon Large Cap Value Inv
RPMMX16.650.05
+0.30%
Reinhart Mid Cap PMV Inv
JUSRX27.330.08
+0.29%
JPMorgan US Equity R5
ABMIX22.290.04
+0.18%
AMG River Road Mid Cap Value I
PIIRX16.99-0.03
-0.18%
Putnam International Value R

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with CGON. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
+0.75%
CGON - ACLX
51%
Loosely correlated
+0.22%
KYMR - ACLX
46%
Loosely correlated
-0.48%
IMNM - ACLX
46%
Loosely correlated
+2.76%
XNCR - ACLX
46%
Loosely correlated
-0.13%
NUVL - ACLX
45%
Loosely correlated
+0.89%
More

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and MOLN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and MOLN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
+15.85%
MOLN - ACUT
21%
Poorly correlated
N/A
PHGE - ACUT
20%
Poorly correlated
-3.38%
TELIF - ACUT
11%
Poorly correlated
-1.62%
BLTE - ACUT
11%
Poorly correlated
+0.32%
ACLX - ACUT
10%
Poorly correlated
+0.75%
More